Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
about
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophreniaGroup II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortexGlutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatmentCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaActivation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats.Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.No evidence for association between polymorphisms in GRM3 and schizophreniaGroup II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsPreclinical models of antipsychotic drug action.Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatmentThinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingEmerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingEpigenetic Mechanisms of Serotonin Signaling.Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex.Metabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A ReviewGlutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophreniaInhibition of evoked glutamate release by neurosteroid allopregnanolone via inhibition of L-type calcium channels in rat medial prefrontal cortexActivation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake ratsMetabotropic glutamate receptors as novel targets for anxiety and stress disordersPrevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysisGenetic dissection of acute ethanol responsive gene networks in prefrontal cortex: functional and mechanistic implicationsAn animal model of emotional blunting in schizophrenia.Regulation of neurotransmitter release by metabotropic glutamate receptorsEffects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats.Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese populationChronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient miceEnhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice.Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunctionEvidence that the gene encoding ZDHHC8 contributes to the risk of schizophreniaSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceThe mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophreniaPerspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionGlutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.Blockade of growth hormone secretagogue receptor 1A signaling by JMV 2959 attenuates the NMDAR antagonist, phencyclidine-induced impairments in prepulse inhibitionNeurophysiological and neurochemical animal models of schizophrenia: focus on glutamateA Role for Oxytocin in the Etiology and Treatment of Schizophrenia.Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813.Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.
P2860
Q24562939-E57E1B6A-9753-4278-B704-67C542DC3658Q24612550-A33B33FC-698E-4C44-A7AF-7C5C625AAD50Q24633004-69314899-34FA-4EF6-83B6-FCE1FC17138DQ24646206-8F2F7B6C-B434-4A18-9F94-DDB0EECEB665Q24652204-68DB1BC2-0002-446C-ADA8-7FCBCB73FBF0Q24657796-F288B2FE-0EBE-4746-8533-F83A8883F48FQ24810205-2881AABE-396A-4273-BEDD-B99D9FE02E3BQ26744729-004C3B55-C558-404B-8EF8-4BE57A92F256Q26827502-2328FA5D-088B-41D7-81CD-36F6006AC965Q26852047-4B46AC51-A2AE-4CB1-9633-EE7774F2F7F8Q26864995-70981564-7BBF-4653-A816-841BF5D02A7BQ27023967-3B03BAA0-1CBB-4065-8DCC-538095105953Q27027985-14AF79A6-24A5-4FEF-89A6-886FCA2CC362Q27308077-AAA5E665-12ED-4720-8A65-CD737FE6BFD3Q27319445-D68284C5-7A7C-47A0-9305-E71A036B977AQ28070122-ABA892C4-378D-4C28-9DBD-8EDCF88D7771Q28210167-F3ED3E74-60EB-4B7A-9FD9-EBF6F3C4B7FAQ28277656-E0AC3ACD-8A7C-4DBE-A466-A7C88C1A32C8Q28297687-1065D4AD-7F76-4BFD-8055-FFCC934A08CBQ28303826-CD25BCE2-F631-4382-80C3-475375F867B0Q28303840-4050E797-1ED4-4686-8EEC-88A28E3E7B22Q28383404-A3C331FA-FDF5-449A-92E6-4339EEB88599Q28471824-748B80DD-C31C-4AC1-BA88-A089E38CCBA4Q28506056-01E1879B-DCC4-44F5-97AA-A6A2C97F0FF2Q28533794-906966CD-9617-4087-BF8C-83FD5B0D4B71Q28539376-70D27CFB-08CA-464E-B6F2-C982DA3D90F2Q28539744-5F280F59-E39E-4EC6-A8EC-1412604C0164Q28585008-5A168A27-A39E-49D0-9647-BEAEA6E4374BQ28590145-8D7CF3BE-5D59-4617-9A56-29789C7BF95AQ28591536-1051E9E6-01CC-4658-BC93-FC56BDD828C8Q29618819-21F319AC-05BD-40EA-AA1C-C792E65D5124Q30371933-B3870418-BB9D-46EC-84C2-98F59D206785Q30379983-A692AAE8-29B1-41F5-A8E0-42C5D1650A91Q30386608-8B71925D-9FB6-4535-B893-09CC1A5F090BQ30387014-4DBF46DC-3343-4E00-B4F7-969C9DB5B0D5Q30400548-763111C0-FADA-481C-BF64-5D68E8BD2636Q30403302-BCA58E5B-DA49-4BA2-8C8F-488CDA60B910Q30408983-2A4F285B-2B73-4070-B5FE-A51410E4B23EQ30418647-9E636F12-006A-4730-B89C-3901075E16DEQ30428213-105E9A08-CA5C-47B1-B683-06EC7C4C00CC
P2860
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@ast
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@en
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@nl
type
label
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@ast
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@en
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@nl
prefLabel
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@ast
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@en
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@nl
P3181
P1433
P1476
Reversal of phencyclidine effe ...... amate receptor agonist in rats
@en
P2093
B Moghaddam
P304
P3181
P356
10.1126/SCIENCE.281.5381.1349
P407
P577
1998-08-28T00:00:00Z